Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. reports developments in mental health care, clinical research operations, and practitioner training tied to regulated botanical wellness-assisted therapies. The company’s updates describe Cedar Clinical Research, Numinus Practitioner Training, clinical trial site readiness, therapist education, protocols, reimbursement infrastructure, and care models for depression, anxiety, trauma, pain, and substance use.
Recurring news also covers quarterly financial results, auditor changes, exchange-listing status, cease-trade-order remediation efforts, and regulatory developments affecting botanical wellness compounds such as ibogaine, MDMA, and LSD.
Numinus Wellness (TSX: NUMI) (OTC: NUMIF), a leader in mental health care, announced its participation in Citi's Psychedelic Drug Call Series on February 2, 2022. The event will feature a fireside chat between Payton Nyquvest, Founder and CEO of Numinus, and Neena Bitritto-Garg, Citi's Biotech analyst, at 10:00 a.m. ET. Numinus focuses on psychedelic-assisted therapies to improve mental health outcomes for conditions like depression and anxiety. More details are available on Numinus' website.
Numinus Wellness reported fiscal Q1 2022 results, showcasing a robust cash position of $53.9 million and a significant 245% year-over-year revenue growth to $0.8 million. The company achieved a gross profit of $50,965, marking a 6.5% gross margin. Notable operational advancements include a clinical trial application for its proprietary psilocybe extract and the initiation of a MAPS-sponsored MDMA-Assisted Therapy study for PTSD. Numinus continues to expand its wellness clinic network, enhancing its capability to provide psychedelic-assisted psychotherapy services.
Numinus Wellness reported strong financial results for Q4 and FY 2021, with revenues increasing by 81% year-over-year to $0.5 million in Q4 and 72% to $1.5 million for the full year. The company boasts a robust cash position of $59.2 million. Despite a gross profit of $31,818 for Q4, Numinus incurred a quarterly loss of $7.8 million, which included a $1.6 million non-cash impairment charge. Key initiatives include the acquisition of the Neurology Centre of Toronto and the launch of clinical trials for psilocybin and MDMA therapies.
Numinus Wellness Inc. (TSXV: NUMI) will change its OTC Pink market ticker symbol to NUMIF from LKYSF on November 22, 2021, enhancing alignment with its TSX-V listing. The company has also gained DTC Eligibility, allowing its shares to be electronically cleared and settled. This move is seen as a critical first step in expanding its U.S. capital markets strategy, according to CEO Payton Nyquvest. Numinus aims to transform mental health care by integrating psychedelic-assisted therapies into mainstream practice.